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TRANSLATIONAL RELEVANCE  
PIM kinases have been recently proposed as new therapeutic targets in 
oncology. PIM447 is the only pan-PIM kinase inhibitor that has reached clinical 
development in MM with promising preliminary efficacy results. In this work, we 
demonstrate through the use of preclinical models the potent anti-myeloma and 
bone protective effects of PIM447, and the mechanisms responsible of such 
effects. In addition, we show the very strong synergy exhibited by this drug in 
combination with different standard-of-care treatments. The preclinical efficacy 
of PIM447 demonstrated in the present work together with the preliminary 
single-agent efficacy and tolerable safety profile observed in the clinical setting, 
reinforces PIM inhibition as a promising therapeutic strategy in myeloma, and 
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Purpose: PIM kinases are a family of serine/threonine kinases recently 
proposed as therapeutic targets in oncology. In the present work, we have 
investigated the effects of the novel pan-PIM kinase inhibitor, PIM447, on 
myeloma cells and myeloma-associated bone disease using different preclinical 
models. 
Experimental Design: In vitro/ex vivo cytotoxicity of PIM447 was evaluated on 
myeloma cell lines and patient samples. Synergistic combinations with standard 
treatments were analyzed with Calcusyn Software. PIM447 effects on bone 
cells were assessed on osteogenic and osteoclastogenic cultures. The 
mechanisms of PIM447 were explored by immunoblotting, qPCR and 
immunofluorescence. A murine model of disseminated multiple myeloma was 
employed for in vivo studies. 
Results: PIM447 is cytotoxic for myeloma cells due to cell cycle disruption and 
induction of apoptosis mediated by a decrease in phospho-Bad (Ser112) and c-
Myc levels and the inhibition of mTORC1 pathway. Importantly, PIM447 
demonstrates a very strong synergy with different standard treatments such as 
bortezomib + dexamethasone (combination index, CI=0.002), lenalidomide + 
dexamethasone (CI=0.065) and pomalidomide + dexamethasone (CI=0.077). 
PIM447 also inhibits in vitro osteoclast formation and resorption, downregulates 
key molecules involved in these processes and partially disrupts the F-actin 
ring, while increasing osteoblast activity and mineralization. Finally, PIM447 
significantly reduced the tumor burden and prevented tumor-associated bone 
loss in a disseminated murine model of human myeloma. 
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Conclusions: Our results demonstrate dual anti-tumoral and bone protective 
effects of PIM447. This fact, together with the very strong synergy exhibited with 
standard-of-care treatments, supports the future clinical development of this 
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Multiple myeloma (MM) is characterized by a proliferation of malignant plasma 
cells in the bone marrow (BM) that secrete a monoclonal immunoglobulin (1). It 
is typically associated with osteolytic lesions, due to an increase in the number 
and bone-resorptive activity of osteoclasts (OCs) together with osteoblast (OB) 
inhibition (2). Over the last decade, the introduction of new drugs, such as 
proteasome inhibitors and immunomodulatory agents, has improved the 
outcome of MM patients (3, 4); however, MM is still considered incurable mainly 
due to the development of drug resistance. Therefore, the identification of new 
targets and the investigation of novel drugs against such targets are extremely 
important for the discovery of more effective treatments (5).  
Recently, PIM kinases have been proposed as being new therapeutic targets 
for treating hematological cancers (6). These are a family of serine/threonine 
kinases comprising three members (PIM1, PIM2 and PIM3), that regulate 
oncogenesis, survival pathways, drug resistance and migration, among other 
functions (7). Several features make PIM inhibition an attractive therapeutic 
strategy, particularly against myeloma cells: i) PIM2 is among the most highly 
over-expressed genes in MM cells (8), ii) this protein is required for maintaining 
MM cell growth (9), and iii) the expression of PIM2 in MM cells is enhanced by 
mesenchymal stromal cells (MSCs) and OCs as a survival and drug resistance 
mechanism (10). In addition, recent studies have also demonstrated the 
importance of PIM kinases in the biology of bone-remodeling cells. Accordingly, 
Kim and colleagues found that PIM1 positively regulates the ligand of the 
receptor activator of NF-κB (RANKL)-induced osteoclastogenesis (11). More 
recently, it has been shown that PIM2 acts as a negative regulator of 
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osteoblastogenesis (12). Based on all these data, it is tempting to hypothesize 
that the inhibition of these proteins would result not only in an anti-tumor 
activity, but may also have a beneficial effect on MM patients’ bone disease.  
PIM447 (N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-
difluorophenyl)-5-fluoropicolinamide) is a potent and selective pan-PIM kinase 
inhibitor, derived from the tool compound LGB321 (6, 9), with pharmacokinetic 
and drug-like properties suitable for clinical development (13). In fact, 
preliminary results from a phase I clinical trial with PIM447 in patients with 
relapsed and/or refractory MM, have demonstrated single agent activity and a 
tolerable safety profile (14). Although the preclinical efficacy of other PIM 
inhibitors has been studied in several hematological malignancies including MM 
(12, 15-18), only two of them, SGI-1776 and AZD1208, have reached clinical 
trials but none in MM.  
In the present work, we have investigated through the use of preclinical models, 
the activity and mechanism of action of PIM447 in myeloma cells, its potential 
synergism with standard-of-care treatments and its effects on myeloma-
associated bone disease. To the best of our knowledge, this is the first clinical 
pan-PIM-inhibitor that demonstrates dual anti-myeloma and bone protective 
effects and this fact, together with the very strong synergy that PIM447 exhibits 
with standard-of-care treatments and the preliminary favorable clinical data, 
supports the future clinical development of this drug for the treatment of MM 
patients. 
   
MATERIALS AND METHODS 
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Drugs. PIM447 was provided by Novartis Pharmaceuticals, Inc. (Basel, 
Switzerland). Bortezomib was purchased from LC Laboratories (Woburn, MA, 
USA), lenalidomide and pomalidomide from Selleckchem (Houston, TX, USA) 
and dexamethasone from Sigma-Aldrich (St Louis, MO, USA).  
Cell lines, primary samples and cultures. The human myeloma cell lines, 
MM1S, MM1R, U266 and NCI-H929 were purchased from ATCC (Manassas, 
VA, USA) whereas RPMI-8226 and OPM-2 were obtained from DSMZ 
(Braunschweig, Germany). The human myeloma cell line MM144 was a 
generous gift from Dr. S. Rudikoff (National Cancer Institute, National Institutes 
of Health, Bethesda, MD, USA). The source of the human myeloma cell lines 
RPMI-LR5, U266-Dox4 and U266-LR7 has been previously described (19). The 
origin of MM1S-luc and RPMI-8226-luc cells (luciferase-expressing) was 
previously explained (20). All myeloma cell lines were cultured as previously 
described (19). The MM1S-luc co-cultures with either the hMSC–TERT cell line 
(obtained from Dr. D. Campana, St. Jude Children’s Research Hospital, 
Memphis, TN) or OCs were performed in the absence or presence of different 
concentrations of PIM447 as previously explained (20). Cell line identities have 
been tested and authenticated by short tandem repeat (STR) analysis with a 
PowerPlex 16 HS System Kit (Promega) and online STR matching analysis 
(DSMZ institute; available from: http:// www.dsmz.de/fp/register.php).  
All primary bone marrow (BM) and peripheral blood samples were obtained 
after the approval of the Complejo Asistencial Universitario de Salamanca 
Review Board and with the written informed consent of all participating subjects.  
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Cell viability, cell cycle and apoptosis assays. Cell viability of myeloma cells 
was evaluated by the MTT method (19). The half-maximal inhibitory 
concentration (IC50) of PIM447 was calculated using SigmaPlot graphing 
software. The cell cycle profile and apoptosis induction were evaluated as 
previously described (21). 
Ex vivo analysis of apoptosis in freshly isolated patient cells. BM samples 
from patients with MM were lysed and cultured as previously described (21), in 
the absence or presence of PIM447. The percentage of annexin-V positive cells 
was analyzed by flow cytometry on myelomatous PCs (CD38+bright, CD45-/low, 
SSClow/intermediate, CD56-/+) and normal lymphocytes (CD45++, SSClow) 
populations. 
Evaluation of the potential synergism of PIM447 with other anti-myeloma 
agents. MM1S or RPMI-8226 cells were treated for 48-72 h with double and 
triple combinations of PIM447 and other anti-myeloma agents (bortezomib, 
lenalidomide, pomalidomide and dexamethasone). Cell viability was analyzed 
by MTT assays. The potency of each combination was quantified with Calcusyn 
software (Biosoft, Ferguson, MO, USA), which is based on the Chou Talalay 
method, yielding a combination index (CI) with the following interpretation: CI>1, 
antagonistic effect; CI=1, additive effect; CI<1, synergistic effect. 
In vitro OC formation, resorption pits and integrity of F-actin ring. 
Peripheral blood mononuclear cells (PBMCs) from healthy donors were 
differentiated in osteoclastogenic medium (containing 25 ng/mL M-CSF and 50 
ng/mL RANKL, both from Peprotech) as previously described (22). Assays 
related to OCs formation and function included: F-actin ring formation (pre-OCs, 
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14 days differentiation), resorption capacity (17 days differentiation), and OC 
formation (21 days differentiation), and were performed as previously reported 
(23). 
In vitro OB differentiation, alkaline phosphatase activity and 
mineralization assays. OBs were generated and assayed as previously 
described (20). Briefly, primary MSCs (passage 2-3) were cultured in 
osteogenic medium (containing 5 mM β-glycerophosphate and 50 mg/mL 
ascorbic acid) and exposed to PIM447. After 11 days, alkaline phosphatase 
(ALP) activity was quantified by hydrolysis of p-nitrophenylphosphate into p-
nitrophenol (Sigma-Aldrich), whereas mineralization was assessed by Alizarin 
Red staining of calcium deposits at day 21. 
Gene expression data: source, processing and analysis. All gene 
expression microarray datasets were retrieved from Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/, accession number: GSE47552) (24). CEL 
files were background-corrected and normalized using the Robust Multi-Array 
(RMA) algorithm implemented in the Affymetrix Expression Console, to estimate 
the log2 normalized expression values for PIM1, PIM2 and PIM3. 
Immunoblotting. Western blot was performed following standard procedures 
(25). Phospho-TSC2 levels were examined with a specific phospho-Akt 
substrate antibody (Cell Signaling Technology; Boston, MA, USA) following 
TSC2 immunoprecipitation, as previously described (9). The origin of primary 
antibodies was as follows: anti-Bcl-2, anti-Mcl-1, anti-p-Erk1/2, anti-NFATc1 and 
anti-cathepsin K from Santa Cruz Biotechnology (Santa Cruz, CA, USA); α-
tubulin from Calbiochem (Billerica, MA, USA); all other antibodies from Cell 
Research. 
on January 9, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 20, 2016; DOI: 10.1158/1078-0432.CCR-16-0230 
11 
 
Signaling Technology. The horseradish peroxidase-conjugated secondary 
antibodies were from GE Healthcare (Little Chalfont, UK).  
Reverse transcription real-time PCR analyses. Total RNA was isolated using 
TRIzol reagent (Invitrogen). TaqMan Gene Expression Assays (Applied 
Biosystems, Waltham, MA USA) were performed according to the 
manufacturer’s instructions: CA2 (Hs00163869_m1), ATP6V1A 
(Hs01097169_m1) and MMP9 (Hs00234579_m1). Normalized gene expression 
was calculated as 2-ΔCt, being ΔCt = Ct (gene) – Ct (GAPDH).  
Mouse model of bone marrow-disseminated human multiple myeloma. 
Animal experiments were conducted according to institutional guidelines for the 
use of laboratory animals, and after granted permission from the University of 
Salamanca Animal Ethical Committee for animal experimentation. RPMI-8226-
luc cells (8 x 106) were injected intravenously into 6-week-old female NOD-
SCID-IL-2Rγ-/- (NSG) mice (Charles River Laboratories, Wilmington, MA, USA) 
and tumor development was monitored by noninvasive bioluminescence 
imaging (BLI), as previously described (20). After 4 weeks, animals were 
randomized into two groups (n=12/group), one receiving vehicle (5 times/week 
by oral gavage), the other receiving PIM447 (100 mg/kg, 5 times/week by oral 
gavage). Serum levels of human Igλ (secreted by RPMI-8226-luc cells) were 
determined by ELISA (Bethyl Laboratories, Montgomery, TX, USA). For 
microcomputed tomography (microCT) analysis, one femur of each animal was 
fixed in 10% formalin and scanned using a microCT system (MicroCATII; 
Siemens) as described previously (22). The trabecular microarchitecture in the 
distal femur was analyzed using BoneJ (26). Carboxy-terminal telopeptide 
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collagen cross-links (CTX) and N-terminal propeptide of type I procollagen 
(P1NP) were measured in mice sera by ELISA (Immunodiagnostic Systems, 
Boldon, Tyne & Wear, UK). 
Statistical analyses. Statistical analyses were performed using SPSS-v21.0 
software (IBM Corp., Armonk, NY, USA). 
 
RESULTS 
PIM kinases are expressed in MM cell lines and myeloma cells from 
patients. We initially evaluated the basal levels of PIM kinases in MM cell lines 
and primary myeloma cells. As shown in Figure 1a, the three isoforms (PIM1, 
PIM2 and PIM3) were expressed in the 10 MM cell lines analyzed. Notably, the 
level of expression of PIM2 was higher than the other two PIM kinases. 
Consistent with these results, we also observed in a series of 41 patients with 
newly-diagnosed MM that PIM2 levels were significantly higher than PIM1 and 
PIM3 in CD138+ myeloma cells (Figure 1b). In addition, PIM1 levels were 
significantly higher than PIM3 levels (Figure 1b).   
PIM447 is cytotoxic for MM cells and overcomes the resistance conferred 
by MSCs and OCs. Since PIM kinases are highly expressed in MM cells, we 
evaluated the anti-myeloma effect of the new pan-PIM kinase inhibitor, PIM447. 
Different MM cell lines were treated with increasing concentrations of PIM447 
(0.05-10 µM) for 24, 48 and 72 h. The dose-response curves obtained by MTT 
assay revealed two patterns of sensitivity: sensitive cell lines with IC50 values at 
48 h ranging from 0.2 to 3.3 µM (MM1S, MM1R, RPMI-8226, MM144, U266 and 
NCI-H929) and less sensitive cell lines with IC50 values at 48 h >7 µM (OPM-2, 
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RPMI-LR5, U266-Dox4 and U266-LR7) (Figure 1c). A lack of correlation was 
found between the levels of PIM kinases and the IC50 values for PIM447 
(p>0.05) (Figure 1d). To explore the induction of apoptosis, three of the 
sensitive cell lines (MM1S, NCI-H929 and RPMI-8226) and two of the less 
sensitive cell lines (OPM-2 and RPMI-LR5) were treated with increasing doses 
of PIM447 for 24 and 48 hours (Figure 2a), revealing a clear dose-response: 
while low doses of the drug (0.1-1 µM) did not induce important levels of 
apoptosis in any of the cell lines tested, PIM447 at 5 µM substantially increased 
annexin-V levels (about 30%) in sensitive cell lines but not in OPM-2 and RPMI-
LR5. In addition, the highest dose (10 µM) induced apoptosis in all the cell lines 
but to a lesser extent in OPM-2 and RPMI-LR5. When MM1S cells were treated 
with 10 µM PIM447 for different times, we observed a time-dependent increase 
in apoptotic cells (Figure 2b). Moreover, treatment of MM1S cells with PIM447 
promoted the cleavage of initiator caspases, such as caspases 8 and 9, and 
also the cleavage of the effector caspases 3 and 7, together with PARP 
cleavage (Figure 2c). Similar results were found in RPMI-8226 and NCI-H929 
cells (Supplementary Figure 1a-b). To assess the potential effect of PIM447 on 
cell cycle, MM1S and OPM-2 cells were incubated with increasing 
concentrations (0.1-10 µM) of this drug for 48 hours, and the cell cycle was 
analyzed by flow cytometry. PIM447 increased the percentage of cells in the 
G0/G1 phase and decreased the proliferative phases (S and G2/M) of the cell 
cycle, in the two cell lines at all doses (Figure 2d). Nevertheless, the effects at 
low concentrations (0.1-1 µM) were more pronounced in MM1S cells than in 
OPM-2. Accordingly, the increase in the percentage of cells in G0/G1 after 
treatment with 0.1, 0.5 or 1 µM PIM447 was, respectively, 10.2%, 16.66% and 
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19.18% in MM1S; and 6.54%, 11.09% and 9.51% in OPM-2. Similar results to 
those of MM1S were found in NCI-H929 (Supplementary Figure 1c). Overall, 
these results indicate that, at least at low doses of the drug, OPM-2 cells are 
less susceptible to cell cycle effects than sensitive cell lines. 
The effect of PIM447 was also investigated ex vivo in cells isolated from BM 
samples from 10 patients with MM, as explained in Methods. After 48 h of 
exposure, PIM447 clearly induced apoptosis in myeloma cells (concentrations 
in the 5-10 µM range) with low to moderate toxicity in lymphocytes (Figure 2e). 
Finally, we investigated whether PIM447 could overcome the protective effect 
conferred by the BM microenvironment on MM cells. For this purpose, MM1S-
luc cells were co-cultured with MSCs or OCs in the presence of PIM447. 
Despite the proliferative advantage conferred by MSCs and OCs, PIM447 
greatly reduced the viability of MM cells under these circumstances (Figure 2f). 
PIM447 potentiates the efficacy of various anti-myeloma agents. Since 
current treatment of MM is largely based on combinations of drugs with different 
mechanisms of action, we studied the effect of combining PIM447 with several 
standard-of-care treatments in MM. The potency of each combination in MM1S 
cells was analyzed with Calcusyn software. With respect to double 
combinations, the synergy (CI<1) of PIM447 with dexamethasone, lenalidomide 
and pomalidomide is noticeable (Figure 3a-c and Supplementary Tables 1, 2 
and 3), being the combination with dexamethasone in the highly synergistic 
range (CI=0.096) at PIM447 200 nM + dexamethasone 10 nM (Figure 3a and 
Supplementary Table 1). On the other hand, triple combinations of PIM447 with 
bortezomib + dexamethasone (Figure 3a and Supplementary Table 1), 
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lenalidomide + dexamethasone (Figure 3b and Supplementary Table 2) and 
pomalidomide + dexamethasone (Figure 3c and Supplementary Table 3) also 
showed a very strong synergism. To confirm these results, the same 
combinations were tested on the RPMI-8226 cell line, rendering similar results 
(Supplementary Figure 2). 
Effect of PIM447 on PIM kinase-related targets. PIM kinases are known to 
directly phosphorylate and regulate the pro-apoptotic Bcl-2 family member, Bad 
(27-29). Accordingly, treatment of MM1S, RPMI-8226 and NCI-H929 cells with 
10 µM PIM447 for different times reduced the phosphorylation of Bad on 
Ser112 without affecting the levels of total Bad (Figure 4a and Supplementary 
Figure 3a). In addition, treatment of MM1S cells with PIM447 reduced the levels 
of the Bad-regulated antiapoptotic protein Bcl-xl, but did not modify the levels of 
other antiapoptotic Bcl-2 family members such as Bcl-2 and Mcl-1 (Figure 4a).  
PIM2 modulates mTORC1 activity and promotes myeloma cell proliferation 
through phosphorylation of TSC2 (9). In this regard, just 1 hour of treatment 
with PIM447 strongly inhibited the phosphorylation of TSC2 in MM1S cells, 
whereas the phosphorylation of PRAS40, another mTORC1 modulator, at 
Thr246 required longer exposure (24 h) to produce a decrease (Figure 4b). In 
addition, treatment of MM1S cells with PIM447 reduced the phosphorylation of 
downstream mTORC1 targets such as 4EBP1 at Thr 37/46, P70S6 at Thr 389 
and S6RP at Ser 235/236 (Figure 4b). Similar results were found for RPMI-8226 
and NCI-H929 cells (Supplementary Figure 3b).  
To gain further insights into the mechanism of PIM447, we analyzed c-Myc, a 
PIM-regulated transcription factor (30). Treatment of MM1S cells with PIM447 
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reduced the levels of total c-Myc and phospho-c-Myc at Ser62, a key residue 
involved in c-Myc stabilization (30) (Figure 4c). The levels of phospho-c-Myc 
(Ser62) also decreased in RPMI-8226 and NCI-H929 cells after treatment with 
PIM447 (Supplementary Figure 3c). Additionally, the levels of Mad-1, a protein 
that antagonizes Myc-mediated transcriptional activity, increased in MM1S after 
PIM447 exposure (Figure 4c). Treatment of MM1S cells with PIM447 also 
reduced the levels of cyclins D2 and E1, two well-known regulators of G1-to-S 
phase transition, previously described as being transcriptionally induced by c-
Myc (31-33) (Figure 4c). 
As previously commented, the sensitivity to PIM447 differs among different MM 
cell lines. In order to elucidate the molecular basis for these differences, we 
explored the molecular effects of PIM447 in the low sensitive cell line OPM-2. 
Treatment of OPM-2 with 10 µM PIM447 reduced the levels of phospho-S6RP 
(Ser 235/236) and phospho-4EBP1 (Thr 37/46) after just 1 hour of treatment, 
indicating the inhibition of the mTORC1 pathway (Supplementary Figure 3d). 
Interestingly, PIM447 did not reduce the levels of phospho-Bad (Ser112) in 
OPM-2, whereas c-Myc and phospho-c-Myc (Ser62) only decreased after 24 
hours of exposure to the drug (Figure 4d). Since the effects of PIM447 on these 
proteins were detected earlier in sensitive cell lines, we then analyzed the 
potential correlation between their basal levels in MM cell lines and the 
sensitivity to PIM447. The analysis showed a strong positive correlation 
between basal levels of Bad and the IC50 for PIM447 (r = 0.8880; p = 0.0006. 
Figure 4e). A positive correlation was also found between basal levels of 
phospho-Bad and IC50 values, although in this case the correlation was not so 
strong (r = 0.6044; p = 0.0642. Figure 4f). Finally, sensitivity to PIM447 does not 
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seem to be associated with basal levels of c-Myc (r = 0.4222; p = 0.2242) or 
phospho-c-Myc (r = 0.4270; p = 0.2184) (Supplementary Figure 4a-b). 
PIM447 inhibits osteoclastogenesis and bone resorption while increasing 
osteoblast activity and mineralization in vitro. Since PIM1 is known to be 
involved in murine RANKL-induced osteoclastogenesis (11), we investigated 
the effect of PIM447 on the formation and function of OCs from human origin. 
First of all, we observed an upregulation of PIM1 and PIM3 during OC 
differentiation (Figure 5a). To evaluate the effect of PIM447 on OC formation, 
human PBMCs were exposed to several concentrations of the drug during OC 
differentiation. PIM447 reduced the number of TRAP+ multinucleated cells 
(IC50=2 µM) derived from PBMCs of healthy donors (Figure 5b). Moreover, 
representative micrographs in Figure 5b illustrate that cell densities were not 
significantly reduced in cultures exposed to up to 5 µM PIM447, suggesting a 
selective effect of PIM447 on inhibition of OC formation rather than on cell 
viability. 
To evaluate changes in OC functionality, we examined the effect of PIM447 on 
osteoclastogenic cultures established on calcium substrate-coated slides. A 
dose-dependent reduction of the area of resorptive pits was observed with 
PIM447 treatment (Figure 5c). Of note, PIM447 inhibited OC-mediated 
resorption at doses clearly lower than those required to inhibit OC formation, 
suggesting that this drug not only inhibits osteoclastogenesis but also directly 
affects OC functionality. 
To gain insight into the mechanisms mediating the aforementioned effects, we 
tested the effect of PIM447 on different transcription factors/molecules involved 
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in OC differentiation and activity. Although levels of PU.1 and p-ERK1/2 were 
not significantly modified, PIM447 treatment reduced the levels of NFATc1, a 
master transcription factor in the differentiation of OCs, and cathepsin K, a 
protease responsible for degradation of organic bone matrix (Figure 5d). We 
also observed that pre-OCs differentiated under PIM447 exposure were 
associated with partial disruption of the F-actin ring (Figure 5e). Expression of 
molecules involved in matrix resorption, such as the matrix metalloproteinase 9 
(MMP9) and the vacuolar-H+-ATPase catalytic subunit A1 (ATP6V1A) were 
significantly diminished after PIM447 treatment (Figure 5f), therefore stating the 
role of PIM447 in preventing bone resorption. Expression of carbonic anhydrase 
II (CA2) also decreased although not reaching statistical significance.  
Since PIM2 has recently been identified as a negative regulator for 
osteoblastogenesis in MM and as an important target for treatment in myeloma 
bone disease (12), we also evaluated whether PIM447 was capable of 
promoting in vitro OB differentiation and activity. Primary MSCs from myeloma 
patients (n=5) were maintained in osteogenic medium in the presence of 
different PIM447 concentrations, and ALP activity was measured at day 11 as a 
surrogate marker of early OB function. As seen in Figure 5g, a significant 
increment in ALP activity was observed after treatment with the pan-PIM kinase 
inhibitor. We also observed a modest increase in matrix mineralization at the 
end of the osteogenic differentiation period (day 21) as assessed by Alizarin 
Red staining of calcium deposits (Figure 5h).  
PIM447 reduces tumor burden and prevents myeloma-associated bone 
loss in a mouse model of disseminated MM. We examined whether the in 
vitro effects of PIM447 were also present in vivo in a disseminated murine 
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model of human myeloma. Compared with the vehicle group, PIM447 clearly 
controlled tumor progression as measured by bioluminescence (Figure 6a) and 
serum levels of hIgλ secreted by RPMI-8226-luc cells (Figure 6b). Importantly, 
PIM447 was well tolerated, as the body weight of mice did not decrease by 
more than 10% (Supplementary Figure 5). 
Representative microCT images at the metaphysis of distal femurs showed 
tumor-associated bone loss in vehicle mice compared with normal bone (mice 
not injected with myeloma cells); in contrast, PIM447-treated animals showed a 
trabecular microarchitecture similar to that of normal bone (Figure 6c). 
Moreover, the analysis of bone morphometric parameters indicated that PIM447 
increased bone volume density and trabecular number and reduced trabecular 
separation relative to vehicle control (Figure 6d). In accordance with these 
findings, the serum levels of the bone resorption marker CTX were significantly 
diminished in PIM447-treated mice (Figure 6e). Although there was a trend for 
PIM447 augmenting serum levels of the bone formation marker P1NP with 
respect to the vehicle-treated group, this was in the limit of statistical 
significance (p=0.06) (Figure 6f).  
 
DISCUSSION 
The search for new targets is of utmost importance in MM because the disease 
is still incurable and the therapeutic options currently available are limited. PIM 
kinases are a family of serine/threonine kinases composed of three members 
(PIM1, PIM2 and PIM3) that have recently been proposed as new therapeutic 
targets in MM (6). Specifically, PIM2 is one of the most highly overexpressed 
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genes in MM (8) and its role as an antiapoptotic and cell growth mediator in 
myeloma cells has been described (9, 10). In line with these data, our results 
demonstrate that the level of expression of PIM2 in myeloma cells is higher than 
the expression of PIM1 and PIM3, suggesting that PIM2 has a major role in the 
biology of MM. Nevertheless, the three PIM kinases have shown some 
functional redundancy in transgenic Eµ-myc mice (34, 35). Since the functional 
overlap of PIM isoforms is also likely to occur in myeloma, it is reasonable to 
hypothesize that the use of pan-PIM inhibitors may be more effective than 
targeting individual isoforms. In this work, we have evaluated in preclinical 
models the efficacy of the novel pan-PIM kinase inhibitor, PIM447, in myeloma 
cells and bone disease.  
PIM447 shows anti-myeloma activity in primary myeloma cells and MM cell 
lines, with different degrees of sensitivity. It is of note that these differences do 
not depend exclusively on basal levels of PIM kinases, since we found a lack of 
correlation between the expression of these proteins and the IC50 values for 
PIM447. On the other hand, interactions between myeloma cells and their 
microenvironment are a crucial factor in myeloma growth and drug resistance 
(36). Here, we have shown in vitro that PIM447 reduces myeloma cell viability 
even in the presence of MSCs and OCs, suggesting that this drug is able to 
overcome microenvironment-mediated drug resistance. Moreover, the clear 
anti-tumoral effect of PIM447 observed in the in vivo murine model of 
disseminated MM, demonstrates the efficacy of this agent in the context of the 
BM microenvironment. 
PIM kinases phosphorylate and regulate multiple targets involved in different 
functions such as cell cycle, apoptosis and metastasis (7). Our results with MM 
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cell lines and patient samples indicate that the cytotoxic effects of PIM447 are 
mediated through cell cycle disruption and induction of apoptosis. The effects at 
low doses of the drug are mainly due to cell cycle arrest rather than apoptosis 
induction, what is concordant with the clinical data, as many of the patients 
treated with the drug in monotherapy achieved stabilization of the disease, 
being some of them quite durable (14). Treatment of myeloma cells with 
PIM447 provokes an increase of cell cycle G0/G1 phase and a decrease of S 
phase, suggesting a cell cycle blockade at the G1-to-S transition. Moreover, 
PIM447 also downregulates the expression of cyclins D2 and E1, two 
fundamental regulators of G1-to-S phase progression (37, 38). In addition, 
PIM447 reduced the levels of the transcription factor c-Myc, a direct target of 
PIM kinases (7), and increased the expression Mad-1, a protein that 
antagonizes Myc-mediated transcriptional activity (39). Since cyclins D2 and E1 
have been described in fibroblast models to be transcriptionally induced by c-
Myc (31-33), it is reasonable to speculate that the reduced expression of these 
cyclins after treatment with PIM447 may be a consequence of the reduction of 
c-Myc levels.  
In addition to cell cycle blockade, the mechanism of PIM447 in myeloma 
involves the induction of apoptosis, as indicated by the increase of annexin-V 
positive cells after treatment, and the cleavage of caspases and their substrate, 
PARP. It should be noted, however, that the levels of apoptosis are quite 
moderate in less sensitive versus sensitive cell lines, even at high doses and 
long times of exposure to the drug. It is well established that PIM kinases 
phosphorylate Bad at Ser112 as an antiapoptotic mechanism (27, 28). 
Accordingly, treatment of sensitive MM cell lines with PIM447 reduced phospho-
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Bad (Ser112) levels, suggesting that apoptosis induction is mediated, at least in 
part, by dephosphorylated Bad which is known to bind and thereby inactivate 
the antiapoptotic proteins Bcl-2 and Bcl-xl (40). In addition, treatment with 
PIM447 also reduced Bcl-xl levels in MM1S, but not Mcl-1 which has been 
shown to be downregulated by PIM inhibition in CLL and MCL (15, 41). On the 
contrary, the levels of phospho-Bad (Ser112) did not decrease after treatment 
with PIM447 in less sensitive cells, suggesting a potential mechanism for 
apoptosis resistance. Moreover, our results indicate that basal levels of Bad and 
phospho-Bad could predict the sensitivity to PIM447, since a positive correlation 
was found between basal levels of these proteins and the IC50 values. Although 
there is no clinical information validating this correlation, the results here 
presented strongly support the study of changes induced in the phosphorylation 
of Bad as a potential biomarker of response to this family of agents. 
Together with the described mechanisms, our results also indicate that PIM447 
represses mTORC1 signaling in myeloma cells. In this regard, treatment with 
PIM447 reduces the phosphorylation of TSC2 and PRAS40, two mTORC1 
inhibitors in their unphosphorylated state (42, 43). The effect on phospho-TSC2 
was detected earlier than the effect on phospho-PRAS40, suggesting that 
PIM447 primarily modulates mTORC1 activity in myeloma cells through TSC2 
(9). As a result of mTORC1 inhibition, there was a decrease in phospho-4EBP1 
and phospho-P70S6, two of its downstream targets implicated in the translation 
of proteins involved in survival, cell cycle progression and the translation 
machinery itself (42, 43). These results indicate that the inhibition of protein 
translation would contribute to PIM447-induced cell death, as previously 
observed with other PIM inhibitors (15-17, 44). 
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A second major finding of our work is the beneficial effect of PIM447 on 
myeloma bone disease. It is known that the interaction between myeloma cells 
and their microenvironment contributes to bone disease as a consequence of 
increased osteoclastogenesis and suppressed osteoblastogenesis (45). 
Moreover, osteolytic lesions are the most common complications of myeloma, 
developing in more than 80% of patients, and associated with decreased overall 
survival (46). This highlights the importance of finding treatments not only 
targeting malignant plasma cells but also having a beneficial effect on bone 
disease. On the one hand, it has been reported that PIM1 positively regulates 
RANKL-induced murine osteoclastogenesis via NFATc1 induction (11). In this 
work, we have shown that both PIM1 and PIM3 expression increase during OC 
differentiation from human PBMCs and, consequently, our in vitro experiments 
show that PIM447 inhibits OC formation and resorptive activity. Mechanistically, 
these effects seem to be mediated, at least in part, by disruption of the F-actin 
ring and downregulation of several molecules involved in OC differentiation and 
function, including NFATc1, the major transcription factor integrating RANKL 
signaling in terminal OC differentiation. On the other hand, PIM2 expression has 
been found to be upregulated in bone marrow MSCs and pre-OBs from 
myeloma patients in the presence of inhibitory factors of osteoblastogenesis in 
myeloma (i.e. IL3, IL7, TNFα, TGFβ, activin A) or after co-culture with MM cells, 
and PIM2 inhibition was able to resume in vitro osteoblastogenesis (12). In 
accordance with the later results, PIM447 treatment of MSCs from myeloma 
patients also significantly increased ALP activity and augmented mineralization 
in in vitro assays. These in vitro effects on bone had their correlate in our 
mouse model of disseminated MM. As observed in the microCT images, the 
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bone trabecular architecture at the metaphyses of distal femurs in PIM447-
treated animals was similar to that of normal bone. In fact, these results match 
with significantly augmented bone parameters of bone volume density and 
trabecular number and reduced trabecular separation. Moreover, significantly 
lower serum levels of CTX (bone resorption marker) were observed in PIM447-
treated animals than in the vehicle control, being indicative of an in vivo effect of 
this drug in reducing OC resorptive activity. PIM447 also augmented levels of 
the bone formation marker P1NP with respect to those mice treated with 
vehicle, although differences did not reach statistical significance. Taken 
together, our data seem to be indicative of PIM447 having anti-myeloma activity 
and preventing bone loss, by both anti-resorptive and bone-anabolic effects. 
This is in line with previous reports showing that PIM2 kinase is an important 
target of treatment for tumor progression and bone loss in myeloma (12). 
One final important point is the very strong synergistic effect observed when 
PIM447 is combined with standard treatments such as dexamethasone, 
bortezomib + dexamethasone, lenalidomide + dexamethasone and 
pomalidomide + dexamethasone. This makes this drug attractive to try to 
improve the efficacy of these standards of care, particularly with oral agents, as 
it would result in effective all-oral combinations.  
Our preclinical results demonstrate the relevance of the new pan-PIM-kinase 
inhibitor, PIM447, in MM as shown by the dual anti-tumoral and bone protective 
effects displayed by this drug. Moreover, in addition to these beneficial effects, 
PIM447 strongly synergizes in vitro with standard-of-care treatments. In 
summary, the present work supports the use of PIM447 in MM patients, 
particularly in combination with the current standards of care.  
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FIGURE LEGENDS 
Figure 1. MM cells express PIM kinases and are sensitive to the anti-
proliferative effect of the pan-PIM kinase inhibitor, PIM447. (a) Basal protein 
levels of PIM1, PIM2 and PIM3 were analyzed by Western blot in 10 MM cell 
lines. α-tubulin was used as a loading control. (b) Basal gene expression of 
PIM1, PIM2 and PIM3, assessed by the Human gene 1.0 ST array (Affymetrix) 
in CD138+ myeloma cells isolated from 41 patients with MM. Normalized 
expression intensity was calculated as described in the Material and Methods. 
An outlier at a distance of greater than 1.5x the interquartile range from the box 
is plotted individually as a dot. Global differences among groups were evaluated 
by the Kruskal–Wallis test; significant pair-wise differences were identified by 
the Mann-Whitney U test. All the p-values were adjusted for multiple 
comparisons using the False Discovery Rate (FDR) method (***P <0.001). (c) 
The indicated MM cell lines were incubated with increasing concentrations of 
PIM447 for 24, 48 and 72 hours and cell viability was analyzed by MTT assay. 
The average absorbance values of control untreated samples were taken as 
Research. 
on January 9, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 20, 2016; DOI: 10.1158/1078-0432.CCR-16-0230 
32 
 
100%. Data are summarized as the mean ± SD (n=3) (d) IC50 values for 
PIM447 at 48 hours were plotted against PIM1, PIM2 and PIM3 expression as 
measured by Western blot and normalized with α-tubulin using the image 
processing package Fiji. r=Pearson correlation coefficient; p=p-value. 
Figure 2. PIM447 induces apoptosis and cell cycle arrest in MM cells and 
overcomes the resistance conferred by MSCs and OCs. (a) MM1S, NCI-
H929, RPMI-8226, OPM-2 and RPMI-LR5 cells were treated with increasing 
doses (0.1-10 µM) of PIM447 for 24 and 48 hours, and the induction of 
apoptosis was analyzed by flow cytometry after annexin-V staining. Data 
represent the percentage of apoptotic cells for each condition after subtracting 
the basal percentage of apoptotic cells for each cell line (b) MM1S cells were 
treated with 10 µM PIM447 for the indicated times, and the induction of 
apoptosis was analyzed by flow cytometry. Data are summarized as the mean ± 
SEM (n=3). Statistically significant differences between control (0 h) and 
different time points are represented as ***P <0.001, **P <0.01 and *P <0.05 
(Student's t-test) (c) MM1S cells were treated with 10 µM PIM447 for the 
indicated times, and the expression of caspase 8, caspase 9, caspase 3, 
caspase 7 and PARP was analyzed by Western blot using α-tubulin as loading 
control. (d) MM1S and OPM-2 cells were incubated with increasing 
concentrations of PIM447 for 48 hours, and the cell cycle profile was examined 
by flow cytometry, as shown by representative histograms. Tables refer to one 
experiment that was repeated twice with similar results in the two cell lines and 
indicate the percentage of cells in subG0 (apoptotic cells) and the percentages 
in G0-G1, S and G2-M from the non-subG0 population. (e) Freshly isolated BM 
cells obtained from 10 patients with MM were treated ex vivo with increasing 
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concentrations of PIM447 for 48 hours. After the incubation period, cells were 
stained with the combination of annexin V-FITC and three monoclonal 
antibodies (CD56-PE, CD45-PerCP-Cy5.5 and CD38-APC) for the analysis of 
apoptosis in myeloma cells and lymphocytes. Outliers further than 1.5x or 3x 
the interquartile range from the box are plotted individually as dots and 
asterisks, respectively. (f) MM1S-luc cells were co-cultured with the hMSC-
TERT cell line for 2 days or pre-OCs derived from healthy donors for 5 days 
with the indicated concentrations of PIM447 and under low-serum conditions. 
After the co-culture period, MM1S-luc growth was assessed by luciferase 
bioluminescence measurement. Graphs illustrate the mean ± SD (n=3).  
Figure 3. PIM447 synergizes with different anti-myeloma agents in the 
MM1S cell line. MM1S cells were treated with the indicated double or triple 
combinations of PIM447, dexamethasone and either (a) bortezomib for 48 
hours, (b) lenalidomide for 72 hours or (c) pomalidomide for 72 hours. Cell 
viability was analyzed by MTT assay as represented in the graphs.  
Figure 4. Effect of PIM447 on PIM kinase-related targets. MM1S or OPM-2 
cells were treated with 10 µM PIM447 for the indicated times and the 
expression of different proteins was analyzed by Western blot. Alpha-tubulin 
was used as a loading control. (a) Protein levels of phospho-Bad (Ser112), total 
Bad, Bcl-2, Bcl-xl and Mcl-1 in MM1S. (b) The levels of phospho-TSC2 in 
MM1S were analyzed by immunoprecipitation of TSC2 with an anti-TSC2 
antibody and subsequent immunoblotting with a phospho-Akt substrate 
antibody. The expression of total TSC2, phospho PRAS40 (Thr246), total 
PRAS40, phospho 4EBP1 (Thr 37/46), total 4EBP1, phospho P70S6 (Thr 389), 
total P70S6, phospho S6RP (Ser 235/236) and total S6RP were analyzed by 
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Western blot. (c) Protein levels of total c-Myc, phospho-c-Myc (Ser 62), Mad-1, 
cyclin D2 and cyclin E1 in MM1S. (d) Protein levels of phospho-Bad (Ser112), 
total Bad, c-Myc and phospho-c-Myc (Ser 62) in OPM-2. (e,f) IC50 values for 
PIM447 at 48 hours were plotted against Bad and phospho-Bad expression, 
respectively, as measured by Western blot and normalized with α-tubulin using 
the image processing package Fiji. r=Pearson correlation coefficient; p=p-value. 
Figure 5. PIM447 inhibits in vitro OC formation and resorption and 
increases OB differentiation and activity. (a) PBMCs were differentiated in 
osteoclastogenic medium for the indicated times. PIM1, PIM2 and PIM3 
expression was analyzed by Western blot. (b) OC formation was evaluated by 
the mean number of TRAP+ multinucleated cells (≥3 nuclei) per well after 
PIM447 treatment of osteoclastogenic cultures for 21 days. Half-maximal 
inhibitory concentration (IC50) of PIM447 was calculated using SigmaPlot 
graphing software. Data are summarized as the mean ± SEM. Representative 
micrographs of TRAP+ OCs are shown. Bar=50 µm. (c) To test the effect of 
PIM447 on OC resorption, inhibition of matrix mineralization was assessed by 
PBMCs cultured on calcium-coated slices in the presence of osteoclastogenic 
medium and PIM447 treatment as indicated. After 17 days, OCs were removed 
and the area of resorbed lacunae analyzed. Data are summarized as the mean 
± SEM. Representative micrographs of resorptive pits after PIM447 treatment 
are reported. Bar=50 µm. Statistically significant differences versus vehicle 
control in b and c were identified by the Mann–Whitney U test (* P <0.05). (d) 
PBMCs were differentiated in osteoclastogenic medium and exposed to 
different concentrations of PIM447. The levels of PU.1, phospho Erk1/2 and 
NFATc1 at day 7 and Cathepsin K at day 14 were analyzed by Western blot, 
Research. 
on January 9, 2018. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 20, 2016; DOI: 10.1158/1078-0432.CCR-16-0230 
35 
 
using α-tubulin as a loading control. (e) Pre-OCs differentiated under PIM447 
exposure for 14 days were stained with rhodamine-conjugated phalloidin and 
examined by fluorescence microscopy to visualize the F-actin ring. 
Representative micrographs are shown. Bar = 50 µm. (f) Normalized gene 
expression of several molecules implicated in OC resorption [MMP9 (matrix 
metalloproteinase 9), ATP6V1A (vacuolar-H+-ATPase catalytic subunit A1) and 
CA2 (carbonic anhydrase II)] after osteoclastogenic differentiation of PBMCs for 
21 days in the presence of PIM447 (2.5 µM), was assessed by real-time RT-
PCR. Relative gene expression was calculated by the 2-ΔCt method, where ΔCt = 
Ct (gene) – Ct (GAPDH). Results are expressed as the mean ± SEM. 
Significant differences with respect to control were assessed with the Student's 
t-test (* P <0.05). (g) Primary bone marrow MSCs from myeloma patients (n=5) 
were maintained in osteogenic medium in the presence of indicated PIM447 
concentrations, and ALP activity (nM/min/µg protein) was measured at day 11. 
Results are expressed as mean ± SEM (** P <0.01 versus control, calculated by 
the Mann-Whitney test) (h) Representative micrographs of matrix mineralization 
by Alizarin Red staining in OBs derived from MSCs from a MM patient (21 days 
of osteogenic differentiation in the presence of PIM447).  
Figure 6. Oral administration of PIM447 decreased tumor burden and 
prevented myeloma-associated bone loss in a mouse model of 
disseminated MM. RPMI-8226-luc cells (8 x 106) were intravenously injected 
into NSG mice. After 4 weeks, mice were randomized into two groups (receiving 
vehicle or PIM447; n=12/group), and treated with dosing and regimen 
schedules as specified. Orally delivered PIM447 effectively reduced tumor 
burden as measured by BLI (a) and serum levels of human Igλ secreted by 
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RPMI-8226-luc cells (b). Data (a and b) are summarized as the mean ± SEM. In 
a, * (P <0.05) represents the first day in which differences with respect to 
vehicle were statistically significant. In b, ***P <0.001 versus vehicle. (c) 
Representative microCT cross-sections at the metaphysis of distal femurs show 
loss of trabecular architecture in vehicle mice with MM, whereas PIM447-
treated mice retain a trabecular microarchitecture similar to that of normal bone 
(mice not injected with myeloma cells; n=4). (d) PIM447 significantly increased 
bone parameters of bone volume density and trabecular number, whereas 
trabecular separation was decreased. Results are summarized as the mean ± 
SEM. Global differences among the three groups were evaluated with the 
Kruskal–Wallis test while pairwise comparisons were evaluated with the Mann-
Whitney U test. All the p-values were adjusted for multiple comparisons using 
the False Discovery Rate (FDR) method: *P <0.05, **P <0.01 and n.s.=not 
significant. (e) PIM447 significantly reduced serum levels of the bone resorption 
marker CTX. *P <0.05 versus vehicle (Student's t-test). (f) PIM447 also 
augmented serum levels of the bone formation marker P1NP with respect to 
vehicle-treated mice, although this change was not found to be significant (P = 
0.06, calculated with the Student´s t-test). Data are expressed as the mean ± 
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